As wild-type FGFR4 has been implicated in fusion-positive RMS cell survival [13], these findings provide a rationale for HSP90 inhibitors in fusion-positive RMSs, as well. Here, FGFR4 is linked to Bannayan-Riley-Ruvalcaba syndrome.